• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed

    2/25/21 3:14:38 PM ET
    $NVCN
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $NVCN alert in real time by email
    SC 13D 1 sc_13d.htm SCHEDULE 13D Schedule 13D

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    NEOVASC INC

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    64065J304

    (CUSIP Number)

    FiveT Investment Management Ltd
    c/o DMS Corporate Services, Suite 5B201, 2nd Floor, One Nexus Way
    Camana Bay, Grand Cayman, Cayman Islands KY1-1108
    +1 345 749 2552

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    February 10, 2021

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    1


    CUSIP No. 64065J304

     

    13D

     

    Page 2 of 6 Pages

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    FiveT Investment Management Ltd

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    WC

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    00,000

     

    8.

     

    SHARED VOTING POWER
     
    00,000

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    00,000

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    00,000

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    00,000

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0.00%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    CO

     

     

     

    2


    CUSIP No. 64065J304

     

    13D

     

    Page 3 of 6 Pages

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    FiveT Capital AG

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    OO

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Switzerland

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    00,000

     

    8.

     

    SHARED VOTING POWER
     
    00,000

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    00,000

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    00,000

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    00,000

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0.00%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    IA

     

     

     

    3


    CUSIP No. 64065J304

     

    13D

     

    Page 4 of 6 Pages

     

     

     

     

    Item 1.  Security and Issuer.

    Cusip:

    64065J304

    Issuer:

    Neovasc Inc
    13562 Maycrest Way
    Richmond, BC V6V 2J7
    Canada

     

    Item 2.  Identity and Background.

    Name of person filing:

    FiveT Investment Management Ltd
    FiveT Capital AG

    Registered address or principle place of business:

    FiveT Investment Management Ltd
    c/o DMS Corporate Services, Suite 5B201, 2nd Floor, One Nexus Way,
    Camana Bay, Grand Cayman, Cayman Islands KY1-1108

    FiveT Capital AG
    Allmendstrasse 140, 8041 Zurich, ZH, Switzerland

     

    Item 5.  Interest in Securities of the Issuer.

    As of the date of this Schedule 13D, the Reporting Persons acquired an aggregate of 3,750,000 shares of Common Stock, consisting of 3,750,000 shares held by the FiveT Investment Management Ltd (the “Shares”).  The Shares represent 5.69% of the Common Stock outstanding.  Subsequently, the Reporting Persons sold an aggregate of 3,750,000 Shares.  As of the date of this Schedule 13D, the Reporting Persons beneficially own an aggregate of 0 shares of Common Stock. The Shares represent 0.00% of the Common Stock outstanding.

     

    Item 7.  Material to Be Filed as Exhibits.

    Schedule I

     

    4


    CUSIP No. 64065J304

     

    13D

     

    Page 5 of 6 Pages

     

     

     

     

     

     

    Schedule I

     

    This Schedule sets forth information with respect to each purchase and sale of Shares which was effectuated by a Reporting Person in the last 60 days since the date of the event which requires filing of this Statement. 

    Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

     

    Trade Date

    Shares Purchased (Sold)

    Price Per Share ($)

    02/10/2021

    3,750,000

    1.84

    02/10/2021

    (3,750,000)

    2.00

     

     

     

     

    5


    CUSIP No. 64065J304

     

    13D

     

    Page 6 of 6 Pages

     

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    FIVET INVESTMENT MANAGEMENT LTD

    /s/ Wieland Kreuder

    Authorized Person

    February 16, 2021

     

     

    6

    Get the next $NVCN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVCN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVCN
    SEC Filings

    See more
    • SEC Form EFFECT filed by Neovasc Inc.

      EFFECT - NEOVASC INC (0001399708) (Filer)

      8/3/23 12:15:07 AM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 15F-12B filed by Neovasc Inc.

      15F-12B - NEOVASC INC (0001399708) (Filer)

      4/24/23 4:15:05 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Neovasc Inc.

      6-K - NEOVASC INC (0001399708) (Filer)

      4/12/23 1:10:18 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Volato Announces Changes to Board Composition

      Volato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024 Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement. The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger

      4/24/24 6:00:00 AM ET
      $BSX
      $SOAR
      $NVCN
      Medical/Dental Instruments
      Health Care
      Transportation Services
      Consumer Discretionary
    • Neovasc Shareholders Approve Acquisition by Shockwave Medical

      Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ:NVCN) (TSX:NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting").The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareholders o

      3/6/23 6:00:00 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • Neovasc Shareholders Approve Acquisition by Shockwave Medical

      VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareh

      3/6/23 5:37:44 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Neovasc Inc. (Amendment)

      SC 13G/A - NEOVASC INC (0001399708) (Subject)

      2/14/22 3:25:50 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13D filed

      SC 13D - NEOVASC INC (0001399708) (Subject)

      2/25/21 3:14:38 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G filed

      SC 13G - NEOVASC INC (0001399708) (Subject)

      2/19/21 4:24:07 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    Financials

    Live finance-specific insights

    See more
    • Volato Announces Changes to Board Composition

      Volato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024 Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement. The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger

      4/24/24 6:00:00 AM ET
      $BSX
      $SOAR
      $NVCN
      Medical/Dental Instruments
      Health Care
      Transportation Services
      Consumer Discretionary
    • Neovasc Announces Third Quarter Financial Results and Provides Corporate Update

      VANCOUVER and MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") ((NASDAQ, TSX:NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to the third quarter of 2021. Accelerating acceptance of Reducer in the UK and French markets, with France the largest volume market in the quarter. Continued enrollment in the COSIRA II pivotal trial, with enrollment expected to be complete in the first half of 2024 and initial data readout in the second half of 2024. In July, 2022, the Company re

      11/10/22 4:05:00 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • Neovasc to Report Third Quarter Financial Results on November 10, 2022

      VANCOUVER and MINNEAPOLIS, Oct. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (NASDAQ ,  TSX : NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm ET on November 10, 2022. Interested parties may access the conference call by dialing (800) 458-4121 or (856) 344-9290 (International) and reference Conference ID 7304031. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc we

      10/27/22 9:00:00 AM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SVB Leerink resumed coverage on Neovasc with a new price target

      SVB Leerink resumed coverage of Neovasc with a rating of Buy and set a new price target of $2.00

      3/14/21 8:09:11 AM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care